Abstract
Since continuous hemofiltration was first described by Peter Kramer as a new form of renal replacement therapy, it has undergone a lot of changes, making it a widely accepted treatment for acute renal failure in critically ill patients. Concomitantly, new insights into the pathogenesis of severe sepsis and septic shock have led to a recent form of immunomodulating therapy for septic shock. In the past decade hemofiltration has gained more importance as a possible treatment of severe sepsis and septic shock. Indeed, various experimental studies have been performed in acute endotoxic or septic shock in different animal models in vivo, focusing on the hemodynamic response. At the same time in vitro studies have studied the removal of different cytokines, both by convection and adsorption.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
